BioSpace News Archive

Skanska has signed a contract with CHRISTUS Health for an expansion to Christus Santa Rosa Hospital-Westover Hills Hospital in San Antonio, Texas, USA.

Shanghai Junshi Biosciences Co., Ltd announces the online publication in New England Journal of the Phase 3 trial comparing the efficacy and safety of VV116 and nirmatrelvir/ritonavir in the treatment of symptomatic patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death.

Asensus Surgical, Inc. announced that Kashiwa Kosei General Hospital in Kashiwa, Japan has entered into an agreement to lease and utilize a Senhance® Surgical System.

Pfizer Inc. announced positive top-line results from the Phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B.

Procaps Group, S.A., a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it will present at the 2023 J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:00 am PST.

Amyris, Inc. announced that it has entered into a definitive purchase agreement for the purchase and sale of 20,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 15,000,000 shares of common stock in a registered direct offering.

ALR Technologies SG Ltd., the diabetes management company, announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd for the Continuous Glucose Monitor hardware used in the GluCurve Pet CGM.

Acer Therapeutics Inc. announced that The Nasdaq Stock Market LLC has formally notified Acer that the company has regained compliance with the $35 million market value of listed securities requirement, and otherwise satisfies all other criteria necessary, for continued listing on The Nasdaq Capital Market.

Hoth Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted an Investigational New Drug application for the company’s HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor inhibitor therapy.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2022.